文献速递妇科

免疫治疗在晚期和复发性错配修复缺陷与错配修复完整子宫内膜癌中的作用

The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2022-12-06

子宫内膜癌在晚期和复发后预后差,一线铂类化疗失败后治疗选择有限。约30%的原发子宫内膜癌和13%至30%的复发性子宫内膜癌为MSI-H/dMMR。KEYNOTE-158、NCT03015129和GARNET试验支持免疫检查点抑制剂单药用于一线治疗失败的晚期或复发性子宫内膜癌,但MMR完整患者未能获得同样结果。KEYNOTE-775更新结果显示,无论MMR状态如何,帕博利珠单抗联合仑伐替尼较化疗显著延长无进展生存期和总生存期;EMA批准后,该联合方案成为子宫内膜癌新的标准二线治疗。

要点

  • 约30%原发子宫内膜癌和13%至30%复发性子宫内膜癌为MSI-H/dMMR。
  • 免疫检查点抑制剂单药在MSI-H/dMMR晚期或复发性子宫内膜癌中显示良好结果。
  • 帕博利珠单抗联合仑伐替尼较化疗显著延长无进展生存期和总生存期,无论MMR状态。

核心结论

  • 帕博利珠单抗联合仑伐替尼在晚期子宫内膜癌患者中较化疗显著延长无进展生存期和总生存期,无论MMR状态。
  • EMA批准后,帕博利珠单抗联合仑伐替尼成为子宫内膜癌患者新的标准二线治疗,无论MMR状态。

研究设计与样本

  • 综述总结了免疫检查点抑制剂在晚期和复发性子宫内膜癌中的相关临床试验结果,包括KEYNOTE-158、澳大利亚NCT03015129、GARNET和KEYNOTE-775等研究。

主要发现

  • 约30%的原发子宫内膜癌为MSI-H/dMMR,13%至30%的复发性子宫内膜癌为MSI-H/dMMR。
  • KEYNOTE-158、澳大利亚NCT03015129和GARNET试验的初步结果强烈支持免疫检查点抑制剂单药用于一线治疗失败的晚期或复发性子宫内膜癌患者。
  • MMR完整患者未能获得免疫检查点抑制剂单药的显著疗效。
  • 免疫检查点抑制剂联合酪氨酸激酶抑制剂显示出非常有说服力的结果。
  • KEYNOTE-775更新结果显示,帕博利珠单抗联合仑伐替尼较化疗显著延长晚期子宫内膜癌患者的无进展生存期和总生存期,无论MMR状态。

关键数值与推荐

  • 约30%的原发子宫内膜癌为MSI-H/dMMR。
  • 13%至30%的复发性子宫内膜癌为MSI-H/dMMR。
  • KEYNOTE-775显示帕博利珠单抗联合仑伐替尼较化疗显著延长无进展生存期和总生存期,无论MMR状态。

临床怎么用

  • EMA批准后,帕博利珠单抗联合仑伐替尼为子宫内膜癌患者新的标准二线治疗,无论MMR状态。
  • 免疫检查点抑制剂单药可用于一线治疗失败的晚期或复发性MSI-H/dMMR子宫内膜癌患者。
  • 进一步研究正在探索免疫检查点抑制剂和酪氨酸激酶抑制剂在一线治疗中的作用,并测试新联合方案(如免疫检查点抑制剂联合PARP抑制剂)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endometrial cancer is the most common gynecological disease in developed countries. Although it is considered an indolent disease, advanced and recurrent endometrial carcinomas are characterized by poor prognosis. In the metastatic setting, after the failure of first-line platinum-based chemotherapy, patients have limited therapeutic options. However, endometrial cancer should not be considered as a single entity but as a group of heterogeneous diseases with specific genomic, molecular, and biological features by suggested the analysis of The Cancer Genome Atlas (TCGA). Accumulating data highlighted the effectiveness and safety of the adoption of immune checkpoint inhibitors (ICIs) for several types of solid tumors. In particular, immunotherapy showed promising results in MSI-H/dMMR solid tumors. Endometrial cancer is not an exception. Endometrial cancer has the highest prevalence of MSI across human cancer types, and approximately 30% of primary endometrial cancers are MSI-H/dMMR and 13% to 30% of recurrent endometrial cancers are MSI-H/dMMR. The preliminary results of the KEYNOTE-158, the Australian NCT03015129 and the GARNET trial strongly supported the adoption of ICIs as monotherapy in patients with advanced or recurrent endometrial cancer, after the failure of first-line treatments. Unfortunately, those impressive results are not achieved in patients with MMR proficient disease. Hence, other combinations were tested. In particular, the adoption of ICIs plus tyrosine kinase inhibitors (TKI) showed very compelling results. Recently, the updated results of the KEYNOTE-775 showed that pembrolizumab plus lenvatinib led to significantly longer progression-free and overall survival than chemotherapy among patients with advanced endometrial cancer, irrespective of MMR status. After EMA approval, pembrolizumab plus lenvatinib represents the new standard second-line treatment in endometrial cancer patients, regardless MMR status. Further studies are investigating the role of ICIs and TKIs in the first line and are testing new combinations (e.g. ICIs plus PARP inhibitors).

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Di Dio C, Bogani G, Di Donato V, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Gynecol Oncol. 2022. PMID: 36493574. doi:10.1016/j.ygyno.2022.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。